Aquatic Capital Management LLC Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Aquatic Capital Management LLC acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,260 shares of the biopharmaceutical company's stock, valued at approximately $324,000.

Several other large investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in Xenon Pharmaceuticals by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after buying an additional 720 shares in the last quarter. KBC Group NV lifted its holdings in shares of Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 780 shares during the last quarter. HighMark Wealth Management LLC grew its position in Xenon Pharmaceuticals by 22.0% in the fourth quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after acquiring an additional 1,100 shares in the last quarter. Swiss National Bank increased its stake in Xenon Pharmaceuticals by 1.0% in the fourth quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company's stock valued at $4,963,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after purchasing an additional 1,414 shares in the last quarter. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Trading Up 0.5 %

Xenon Pharmaceuticals stock opened at $38.28 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00. The firm has a market cap of $2.93 billion, a P/E ratio of -13.57 and a beta of 1.21. The firm has a 50-day moving average of $34.74 and a 200-day moving average of $38.57.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05. Research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on XENE shares. The Goldman Sachs Group reduced their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. HC Wainwright reissued a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday. Finally, Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $56.78.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.